IQZ23 inhibits adipocyte differentiation via AMPK pathway activation. IQZ23 exerts a high efficacy in decreasing the triglyceride level (EC50=0.033 μM) in 3T3-L1 adipocytes. IQZ23 could be used for the research of obesity and related metabolic disorders.

Product information

CAS Number: 2415643-79-5

Molecular Weight: 443.54

Formula: C26H29N5O2

Chemical Name: 5-methoxy-2-(4-{[4-(pyrrolidin-1-yl)butyl]amino}quinazolin-2-yl)-1H-indole-3-carbaldehyde

Smiles: COC1C=C2C(C=O)=C(NC2=CC=1)C1=NC(NCCCCN2CCCC2)=C2C=CC=CC2=N1

InChiKey: HPSVWLBMFVRSNF-UHFFFAOYSA-N

InChi: InChI=1S/C26H29N5O2/c1-33-18-10-11-23-20(16-18)21(17-32)24(28-23)26-29-22-9-3-2-8-19(22)25(30-26)27-12-4-5-13-31-14-6-7-15-31/h2-3,8-11,16-17,28H,4-7,12-15H2,1H3,(H,27,29,30)

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

IQZ23 activates AMPK pathway by modulating ATP synthase activity. IQZ23 (0.3 and 1.0 μM) markedly decreases the protein level of adipogenic factors C/EBPα, PPARγ, and sterol regulatory element-binding protein 1c (SREBP-1c)) after 24 h treatment as well as the level of fatty acid synthesis related proteins fatty acid synthase (FAS), acetyl CoA carboxylase (ACC), stearoyl-CoA desaturase 1 (SCD1) after 6 days of treatment in 3T3-L1 adipocytes.

In Vivo:

IQZ23 (20 mg/kg, i.p.) treatment significantly reverses high fat and cholesterol diet (HFC)- induced body weight increases and accompanying clinical symptoms of obesity in mice but without indicative toxicity. IQZ23 exhibits moderate terminal elimination half-lives (rat 4.2±0.3 h) and Cmax (rat 37.1±7.0 ng/mL) following oral administration (rat 5 mg/kg). IQZ23 exhibits terminal elimination half-lives (rat 4.4±0.4 h) following intravenous administration (rat 2 mg/kg).

Products are for research use only. Not for human use.